民生证券近期研报指出，关注2024年12月参议院日程及排期，单独立法方面H.R.8333相关进展；美联储降息50bp，biotech融资端有望延续上半年改善趋势，以海外客户为主要订单和收入贡献的CXO龙头有望进一步回暖。The rise of CRO concept stocks has further widened. As of the time of this report, wuxi apptec (02359) rose by 10%, reaching 55 Hong Kong dollars; pharmaron (03759) rose by 8.12%, reaching 14.64 Hong Kong dollars; wuxi bio (02269) rose by 7.02%, reaching 17.6 Hong Kong dollars.
According to Zhitong Finance APP, the increase in CRO concept stocks has further expanded. As of this report, wuxi apptec (02359) rose by 10%, reaching 55 Hong Kong dollars; pharmaron (03759) rose by 8.12%, reaching 14.64 Hong Kong dollars; wuxi bio (02269) rose by 7.02%, reaching 17.6 Hong Kong dollars; joinn laboratories (06127) rose by 5.62%, reaching 9.4 Hong Kong dollars.
On the news front, market reports suggest that usa lawmakers are considering changes to the legislation, with the compromise version including increased administrative review processes for related companies, rather than an automatic ban on biotech companies from collaborating with china. These potential revisions involve a key part of the legislation that specifically names chinese companies.
Minsheng Securities' recent research reports indicate attention to the Senate schedule and timelines for December 2024, as well as the related progress of the standalone legislation H.R.8333; the Federal Reserve's interest rate cut of 50 basis points is expected to continue the improvement trend in biotech financing from the first half of the year, with CXO leaders, primarily contributing orders and revenue from overseas clients, expected to further recover.
